EVESA

Welcome to the Brand page for “EVESA”, which is offered here for Line 6, cancer should be deleted.;pharmaceuticals for use in stimulating human blood cell production; pharmaceuticals for the treatment of anemia, ischemia, myocardial infarction, congestive heart failure, renal failure, anoxia-induced cellular degeneration, hypoxia-induced cellular degeneration and stroke;.

Its status is currently believed to be active. Its class is unavailable. “EVESA” is believed to be currently owned by “Affymax Pharma Limited”.


Owner:
AFFYMAX PHARMA LIMITED
Owner Details
Description:
Line 6, cancer should be deleted.;Pharmaceuticals for use in stimulating human blood cell production; pharmaceuticals for the treatment of anemia, ischemia, myocardial infarction, congestive heart failure, renal failure, anoxia-induced cellular degeneration, hypoxia-induced cellular degeneration and stroke;
Categories: LINE